Abbott Laboratories (ABT)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 55.59% | 54.70% | 54.38% | 54.15% | 54.16% | 54.97% | 55.21% | 55.50% | 56.15% | 57.11% | 58.05% | 57.04% | 56.97% | 56.83% | 55.74% | 56.82% | 56.65% | 56.72% | 57.59% | 58.40% |
| Operating profit margin | 16.55% | 16.73% | 16.71% | 16.73% | 17.39% | 16.05% | 15.95% | 17.17% | 19.16% | 20.95% | 22.42% | 20.73% | 19.56% | 20.04% | 18.46% | 17.97% | 15.48% | 13.39% | 12.78% | 14.18% |
| Pretax margin | 16.72% | 16.44% | 15.98% | 16.21% | 16.61% | 15.49% | 15.60% | 16.85% | 19.03% | 20.68% | 22.06% | 20.32% | 19.06% | 19.55% | 17.90% | 17.08% | 14.36% | 11.86% | 11.14% | 12.71% |
| Net profit margin | 31.95% | 13.99% | 13.65% | 13.96% | 14.27% | 12.92% | 12.83% | 13.98% | 15.88% | 17.52% | 18.78% | 17.35% | 16.42% | 17.12% | 15.85% | 15.33% | 12.99% | 10.50% | 9.89% | 11.15% |
The profitability ratios of Abbott Laboratories show fluctuations over the periods provided.
1. Gross Profit Margin: The gross profit margin has been relatively stable, ranging from 54.16% to 58.40% over the analyzed period. The margins saw a slight decrease from 2023 to 2024, indicating potential challenges in maintaining product costs.
2. Operating Profit Margin: Abbott Laboratories' operating profit margin demonstrates variability, with values fluctuating between 12.78% and 22.42%. The margin peaked in June 2022 but experienced a decline towards the end of the period, hovering around 16-20% by 2024.
3. Pre-tax Margin: The pre-tax margin of Abbott Laboratories exhibited a similar trend to the operating profit margin, showing significant fluctuations. The margin ranged from 11.14% to 22.06%, with peaks in June 2022, followed by a gradual decline.
4. Net Profit Margin: The net profit margin displays the company's bottom-line profitability, ranging from 9.89% to 31.95%. Notably, there was a significant spike in net profit margin in December 2024 compared to previous periods, indicating a substantial increase in profitability.
Overall, Abbott Laboratories experienced fluctuations in profitability ratios during the analyzed period, with some margins improving while others declining. It is important for stakeholders to monitor these ratios for ongoing financial health assessment and future decision-making.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 8.53% | 9.27% | 9.32% | 9.31% | 9.53% | 8.90% | 8.75% | 9.66% | 11.23% | 12.96% | 13.76% | 12.47% | 11.20% | 11.49% | 10.14% | 9.22% | 7.38% | 6.25% | 5.84% | 6.82% |
| Return on assets (ROA) | 16.46% | 7.76% | 7.61% | 7.77% | 7.82% | 7.16% | 7.04% | 7.87% | 9.31% | 10.84% | 11.53% | 10.44% | 9.40% | 9.82% | 8.70% | 7.86% | 6.20% | 4.90% | 4.52% | 5.36% |
| Return on total capital | 16.06% | 18.92% | 18.30% | 18.13% | 18.48% | 17.47% | 17.89% | 10.05% | 24.09% | 28.93% | 30.31% | 29.77% | 27.10% | 27.41% | 24.46% | 20.96% | 17.28% | 14.31% | 14.06% | 15.99% |
| Return on equity (ROE) | 28.12% | 14.49% | 14.13% | 14.51% | 14.83% | 13.77% | 13.88% | 7.82% | 18.90% | 22.11% | 23.44% | 21.82% | 19.75% | 21.04% | 18.86% | 17.06% | 13.71% | 10.78% | 10.17% | 11.84% |
The profitability ratios of Abbott Laboratories show a positive trend over the periods under review.
- Operating return on assets (Operating ROA) increased steadily from 6.82% on March 31, 2020, to 13.76% on June 30, 2022, before slightly decreasing to 8.53% on December 31, 2024.
- Return on assets (ROA) also displayed a similar pattern, rising from 5.36% on March 31, 2020, to a peak of 16.46% on December 31, 2024, indicating improving efficiency in generating profits from the company's assets.
- Return on total capital demonstrated consistent growth, reaching a high of 30.31% on June 30, 2022, before declining marginally to 16.06% on December 31, 2024.
- Return on equity (ROE) exhibited a positive trajectory, climbing from 11.84% on March 31, 2020, to a peak of 28.12% on December 31, 2024, indicating effective utilization of equity capital to generate returns for shareholders.
Overall, the profitability ratios of Abbott Laboratories show a strong and improving performance in terms of generating profits from assets, capital, and equity over the periods analyzed.